Skip to main content
SpringerLink
Log in
Book cover

Neuro-Geriatrics pp 125–139Cite as

Parkinson’s Disease

  • Chapter
  • First Online:

  • 1210 Accesses

Abstract

Parkinson disease (PD) is the second most common neurodegenerative disease after Alzheimer disease, affecting about 2% of the population over the age of 60. The prevalence of PD rises from 107/100,000 persons in age 50–59 years to 1087/100,000 persons in age 70–79 years. As our population ages, the estimated cost of PD will also continue to rise as more than 11,000 patients receive home healthcare for PD, and between 2.2 and 6.8% of the nursing home population has PD. Greater disease severity, and the presence of motor complications and cognitive issues have been correlated with higher costs and lower rates of employment. Therefore, it is imperative to diagnose and optimally manage PD as early as possible. Currently there are no diagnostic tests that confirm the diagnosis of PD, however diagnosis is based on the presence of a constellation of symptoms including: bradykinesia, rigidity, tremor, and gait abnormality/postural instability. This chapter will review the current diagnostic criteria and approach to diagnosis and management of PD.

This is a preview of subscription content, log in via an institution.

References

  1. Pringsheim T, Jette N, Frolkis A, Steeves TD. The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Mov Disord. 2014;29(13):1583–90.

    Article  PubMed  Google Scholar 

  2. Dodel RC, Singer M, Kohne-Volland R, et al. The economic impact of Parkinson’s disease: an estimation based on a 3-month prospective analysis. PharmacoEconomics. 1998;14(3):299–312.

    Article  CAS  PubMed  Google Scholar 

  3. Findley L, Aujla M, Bain PG, et al. Direct economic impact of Parkinson’s disease: a research survey in the United Kingdom. Mov Disord. 2003;18(10):1139–45.

    Article  PubMed  Google Scholar 

  4. Chrischilles EA, Rubenstein LM, Voelker MD, et al. The health burdens of Parkinson’s disease. Mov Disord. 1998;13(3):406–13.

    Article  CAS  PubMed  Google Scholar 

  5. Goetz CG, Stebbins GT. Risk factors for nursing home placement in Parkinson’s disease. Ann Neurol. 1992;32(2):250.

    Google Scholar 

  6. The average per-patient costs of Parkinson’s disease. New York: John Robbins Associates; 1998.

    Google Scholar 

  7. Cooper JA, et al. Slowed central processing in simple and go/no-go reaction time tasks in Parkinson’s disease. Brain. 1994;117(3):517–29.

    Article  PubMed  Google Scholar 

  8. Jankovic J, Schwartz KS, Ondo W. Re-emergent tremor of Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1999;67(5):646–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Rodriguez-Oroz MC, et al. Initial clinical manifestations of Parkinson’s disease: features and pathophysiological mechanisms. Lancet Neurol. 2009;8(12):1128–39.

    Article  CAS  PubMed  Google Scholar 

  10. Jankovic J, et al. Movement and reaction times and fine coordination tasks following pallidotomy. Mov Disord. 1999;14(1):57–62.

    Article  CAS  PubMed  Google Scholar 

  11. Broussolle E. Contribution of Jules Froment to the study of Parkinsonian rigidity. Mov Disord. 2007;22:909–14.

    Article  PubMed  Google Scholar 

  12. Tyrrell P, Rossor M. The association of gegenhalten in the upper limbs with dyspraxia. J Neurol Neurosurg Psychiatry. 1988;51(7):995–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Fitzgerald PM, Jankovic J. Lower body parkinsonism: evidence for vascular etiology. Mov Disord. 1989;4:249–60.

    Article  CAS  PubMed  Google Scholar 

  14. Winikates J, Jankovic J. Clinical correlates of vascular parkinsonism. Arch Neurol. 1999;56(1):98–102.

    Article  CAS  PubMed  Google Scholar 

  15. Goetz CG, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129–70.

    Article  PubMed  Google Scholar 

  16. Bernal-Pacheco O, et al. Nonmotor manifestations in Parkinson disease. Neurologist. 2012;18(1):1–16.

    Article  PubMed  Google Scholar 

  17. Fernandez HH. Updates in the medical management of Parkinson disease. Cleve Clin J Med. 2012;79(1):28–35.

    Article  PubMed  Google Scholar 

  18. Stern MB, et al. Olfactory function in Parkinson’s disease subtypes. Neurology. 1994;44(2):266–8.

    Article  CAS  PubMed  Google Scholar 

  19. Katzenschlager R, Lees AJ. Olfaction and Parkinson’s syndromes: its role in differential diagnosis. Curr Opin Neurol. 2004;17(4):417–23.

    Article  PubMed  Google Scholar 

  20. Garcia-Borreguero D, Larrosa O, Bravo M. Parkinson’s disease and sleep. Sleep Med Rev. 2003;7(2):115–29.

    Article  PubMed  Google Scholar 

  21. Oerlemans WG, de Weerd AW. The prevalence of sleep disorders in patients with Parkinson’s disease: a self-reported, community-based survey. Sleep Med. 2002;3:147–9.

    Article  PubMed  Google Scholar 

  22. Factor SA, McAlarney T, Sanchez-Ramos JR, Weiner WJ. Sleep disorders and sleep effect in Parkinson’s disease. Mov Disord. 1990;5(4):280–5.

    Article  CAS  PubMed  Google Scholar 

  23. Ondo WG, Vuong KD, Jankovic J. Exploring the relationship between Parkinson disease and restless legs syndrome. Arch Neurol. 2002;59(3):421–4.

    Article  PubMed  Google Scholar 

  24. Krishnan PR, Bhatia M, Behari M. Restless legs syndrome in Parkinson’s disease: a case-controlled study. Mov Disord. 2003;18(2):181–5.

    Article  PubMed  Google Scholar 

  25. Postuma RB, Gagnon JF, Rompré S, Montplaisir JY. Severity of REM atonia loss in idiopathic REM sleep behavior disorder predicts Parkinson disease. Neurology. 2010;74(3):239–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Senard JM, Raï S, Lapeyre-Mestre M, et al. Prevalence of orthostatic hypotension in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1997;63(5):584–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Bonuccelli U, et al. Orthostatic hypotension in de novo Parkinson disease. Arch Neurol. 2003;60(10):1400–4.

    Article  PubMed  Google Scholar 

  28. Brigo F, Matinella A, Erro R, Tinazzi M. [123I]FP-CIT SPECT (DaTSCAN) may be a useful tool to differentiate between Parkinson’s disease and vascular or drug-induced parkinsonisms: a meta-analysis. Eur J Neurol. 2014;21:1369–e90. doi:10.1111/ene.12444.

    Article  CAS  PubMed  Google Scholar 

  29. Postuma RB, Berg D, Stern M, Poewe W, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30(12):1591–9.

    Article  PubMed  Google Scholar 

  30. Fernandez HH, Machado AG, Pandya M. A practical approach to movement disorders. New York: Demos Medical; 2015.

    Google Scholar 

  31. Fahn S. The history of dopamine and levodopa in the treatment of Parkinson’s disease. Mov Disord. 2008;23(S3):S497–508.

    Article  PubMed  Google Scholar 

  32. Holloway RG, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol. 2004;61(7):1044–53.

    PubMed  Google Scholar 

  33. Metman LV, et al. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch Neurol. 1999;56(11):1383–6.

    Article  CAS  PubMed  Google Scholar 

  34. Parkinson Study Group. DATATOP: a multicenter controlled clinical trial in early Parkinson’s disease. Arch Neurol. 1989;46(10):1052–60.

    Article  Google Scholar 

  35. Olanow CW, Rascol O, Hauser R, et al.; ADAGIO Study Investigators. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N Engl J Med. 2009;361(13):1268–78.

    Google Scholar 

  36. Parkinson Study Group. A randomized placebo-controlled trial of rasagilin in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol. 2005;62(2):241–8.

    Article  Google Scholar 

  37. Rascol O, Brooks DJ, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study):a randomized, double-blind, parallel-group trial. Lancet. 2005;365(9463):947–54.

    Article  CAS  PubMed  Google Scholar 

  38. Alberts JL, et al. It is not about the bike, it is about the pedaling: forced exercise and Parkinson’s disease. Exerc Sport Sci Rev. 2011;39(4):177–86.

    PubMed  Google Scholar 

  39. Reuter I, Engelhardt M, Stecker K, Baas H. Therapeutic value of exercise training in Parkinson’s disease. Med Sci Sports Exerc. 1999;31(11):1544–9.

    Article  CAS  PubMed  Google Scholar 

  40. Rodrigues de Paula F, et al. Impact of an exercise program on physical, emotional, and social aspects of quality of life of individuals with Parkinson’s disease. Mov Disord. 2006;21(8):1073–7.

    Article  PubMed  Google Scholar 

Additional information can be found in

  • Factor SA, Weiner W. Parkinson’s disease: diagnosis & clinical management. 2nd ed. Demos Medical; 2008.

    Google Scholar 

  • Fahn S, Jankovic J, Hallett M. Principles and practice of movement disorders. Elsevier Health Sciences; 2011.

    Google Scholar 

Download references

Disclosures

Shnehal Patel, Sergio Ramirez, and Joseph Rudolph have no disclosures. Hubert Fernandez has received research support from Abbvie, Acadia, Auspex, Biotie Therapeutics, Civitas, Kyowa/Prostrakan, Michael J. Fox Foundation, Movement Disorders Society, NIH/NINDS, Parkinson Study Group, Rhythm, Synosia, Teva, but has no owner interest in any pharmaceutical company. Dr. Fernandez has received honoraria from Prime Education Inc., Ohio State University, International Parkinson and Movement Disorders Society, Carling Communications, Medscape, as a speaker in CME events. Dr. Fernandez has received honoraria from Biogen, GE Health Care, Lundbeck, Merz Pharmaceuticals and Pfizer Pharmaceuticals, as a consultant. Dr. Fernandez has received royalty payments from Demos Publishing for serving as a book author/editor. The Cleveland Clinic has contracts with Abbvie and Merz Pharmaceuticals for Dr. Fernandez’ role as a member of the Global Steering Committee for LCIG studies and as a consultant or speaker; and Head Principal Investigator for the Xeomin Registry Study. Dr. Fernandez also serves as the Chair of the Publication Committee for Xeomin Studies (Merz Pharmaceuticals); a member of the Publication Committee for Dysport studies (Ipsen Pharmaceuticals) but he does not receive any personal compensation for these roles. Dr. Fernandez has received a stipend from International Parkinson and Movement Disorders Society for serving as Medical Editor of the MDS Web Site.

Author information

Authors and Affiliations

  1. Cleveland Clinic Center of Neurologic Restoration, 9500 Euclid Avenue, #U2, Cleveland, OH, 44105, USA

    Shnehal Patel M.D., M.P.H., Sergio Ramirez M.D., Joseph Rudolph M.D. & Hubert H. Fernandez M.D.

Authors
  1. Shnehal Patel M.D., M.P.H.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sergio Ramirez M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joseph Rudolph M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hubert H. Fernandez M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hubert H. Fernandez M.D. .

Editor information

Editors and Affiliations

  1. Lou Ruvo Center for Brain Health, Cleveland Clinic, Neurological Institute, Cleveland, Ohio, USA

    Babak Tousi

  2. Lou Ruvo Center for Brain Health, Cleveland Clinic, Las Vegas, Nevada, USA

    Jeffrey Cummings

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Patel, S., Ramirez, S., Rudolph, J., Fernandez, H.H. (2017). Parkinson’s Disease. In: Tousi, B., Cummings, J. (eds) Neuro-Geriatrics. Springer, Cham. https://doi.org/10.1007/978-3-319-56484-5_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-56484-5_10

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-56483-8

  • Online ISBN: 978-3-319-56484-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation